{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:08:38Z","timestamp":1768349318823,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.msard.2020.102109","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T21:46:15Z","timestamp":1588023975000},"page":"102109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-812X","authenticated-orcid":false,"given":"Young-Min","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0264-4531","authenticated-orcid":false,"given":"Hyunjin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0287-7589","authenticated-orcid":false,"given":"Hye Weon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwa Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang-Kuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2020.102109_bib0001","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1017\/S0317167100053932","article-title":"Devic\u2019s neuromyelitis optica treated with intravenous gamma globulin (IVIG)","volume":"31","author":"Bakker","year":"2004","journal-title":"Can. J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.msard.2020.102109_bib0002","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2020.102109_bib0003","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2020.102109_bib0004","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40265-018-1039-7","article-title":"Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options","volume":"79","author":"Collongues","year":"2019","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.msard.2020.102109_bib0005","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"issue":"10","key":"10.1016\/j.msard.2020.102109_bib0029","doi-asserted-by":"crossref","first-page":"e4.65","DOI":"10.1136\/jnnp-2014-309236.157","article-title":"IVIG IN NMO REFRACTORY\/INTOLERANT TO RITUXIMAB","volume":"85","author":"Elsone","year":"2014","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"3","key":"10.1016\/j.msard.2020.102109_bib0006","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/WCO.0000000000000694","article-title":"Neuromyelitis optica spectrum disorders: still evolving and broadening","volume":"32","author":"Fujihara","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2020.102109_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17091407","article-title":"Efficacy of polyvalent human immunoglobulins in an animal model of neuromyelitis optica evoked by intrathecal anti-aquaporin 4 antibodies","volume":"17","author":"Grunewald","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2020.102109_bib0030","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA neurology"},{"issue":"8","key":"10.1016\/j.msard.2020.102109_bib0008","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/1352458511431728","article-title":"Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature","volume":"18","author":"Jarius","year":"2012","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2020.102109_bib0009","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2020.102109_bib0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","article-title":"Present and Future therapies in neuromyelitis optica spectrum disorders","volume":"13","author":"Kleiter","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"20","key":"10.1016\/j.msard.2020.102109_bib0011","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients","volume":"78","author":"Leite","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2020.102109_bib0012","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"issue":"9451","key":"10.1016\/j.msard.2020.102109_bib0013","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"Pt 7","key":"10.1016\/j.msard.2020.102109_bib0014","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.msard.2020.102109_bib0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s13311-015-0391-5","article-title":"Efficacy of intravenous immunoglobulin in neurological diseases","volume":"13","author":"Lunemann","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.msard.2020.102109_bib0016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nrl.2012.03.014","article-title":"The effect of intravenous immunoglobulin on neuromyelitis optica","volume":"28","author":"Magraner","year":"2013","journal-title":"Neurolog\u00eda"},{"issue":"19","key":"10.1016\/j.msard.2020.102109_bib0017","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2169\/internalmedicine.46.0217","article-title":"Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica","volume":"46","author":"Okada","year":"2007","journal-title":"Intern. Med."},{"issue":"6","key":"10.1016\/j.msard.2020.102109_bib0018","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol."},{"issue":"13","key":"10.1016\/j.msard.2020.102109_bib0019","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0b013e31824de293","article-title":"Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the therapeutics and technology assessment subcommittee of the American academy of neurology","volume":"78","author":"Patwa","year":"2012","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2020.102109_bib0020","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00401-013-1172-z","article-title":"Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica","volume":"126","author":"Ratelade","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.msard.2020.102109_bib0021","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.expneurol.2014.03.004","article-title":"Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica","volume":"255","author":"Ratelade","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.msard.2020.102109_bib0028","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.neuropharm.2018.02.002","article-title":"Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica","volume":"133","author":"Tradtrantip","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.msard.2020.102109_bib0022","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.msard.2019.04.021","article-title":"Successful intravenous immunoglobulin treatment in relapsing MOG-antibody-associated disease","volume":"32","author":"Tsantes","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102109_bib0023","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jneuroim.2015.03.021","article-title":"Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica","volume":"282","author":"Viswanathan","year":"2015","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.msard.2020.102109_bib0024","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2020.102109_bib0025","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2020.102109_bib0026","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","article-title":"Neuromyelitis optica: clinical predictors of a relapsing course and survival","volume":"60","author":"Wingerchuk","year":"2003","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2020.102109_bib0027","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/acn3.326","article-title":"Dose-dependent inhibition of demyelination and microglia activation by IVIG","volume":"3","author":"Winter","year":"2016","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820301863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820301863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:51:21Z","timestamp":1761900681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820301863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":30,"alternative-id":["S2211034820301863"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102109","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102109"}}